Selexis SA has signed additional commercial license agreements (CLAs) with Agenus Inc.   Under the new CLAs, Agenus will leverage Selexis’ modular SUREtechnology Platform for the rapid, stable, and cost-effective production of its therapeutic proteins.  “It’s gratifying to have the opportunity to play a part in Agenus’ mission to redefine cancer treatment by advancing promising new biologics for individuals living with cancer,” said Yemi Onakunle, PhD, MBA, Selexis vice president,...